Citi lowered the firm’s price target on Candel Therapeutics (CADL) to $22 from $24 and keeps a Buy rating on the shares. The firm says the company’s recent financings support its lung cancer trial start in Q2 and planned prostate launch in 2027. Citi cites dilution for the target cut.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Restrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk
- Candel Therapeutics: Advancing CAN-2409 Toward a 2026 BLA on Strengthening Prostate Cancer Data and Solid Cash Runway
- Candel Therapeutics: Advancing CAN-2409 Toward BLA With Platform-Like Oncology Potential and Diversified Pipeline Upside
- Candel Therapeutics reports Q4 EPS (54c) vs. (40c) last year
- Candel Therapeutics sees cash runway into 1Q28